real-time news and commentary for investors
Monday, Sep 9
XenoPort announces preliminary results from Phase I studies of its potential MS treatment, XP23829
- XenoPort (XNPT) announces favorable preliminary results from two Phase I studies of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate.
- Based on the results, the drug developer intends to continue to advance the development of XP23829 as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.
- The company plans to finalize dose and formulation selection as well as other aspects of its development plans over the next few months.